Progress in comprehensive treatment of pulmonary large cell neuroendocrine carcinoma
Liu Ningbo, Luo Jing, Zhao Lujun, Wang Ping
Department of Radiation Oncology,Cancer Hospital of Tianjin Medical University,Tianjin Malignant Tumor Clinical Medicine Research Center,Tianjin"Tumor Prevention and Control" Key Laboratory,National Cancer Clinical Medical Research Center,Tianjin 300060,China
Abstract：Large cell neuroendocrine carcinoma is not very common,and it has a high degree of malignancy and invasion,outcome is also poor. Even LCLC is defined as non-small cell lung cancer,its biological and clinical characteristics,prognostic factors are similar to small cell lung cancer. The treatment for LCLC is still controversial. The research progress on comprehensive treatment of lung large cell neuroendocrine carcinoma was reviewed.
Liu Ningbo,Luo Jing,Zhao Lujun et al. Progress in comprehensive treatment of pulmonary large cell neuroendocrine carcinoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(10): 792-795.
[1] Rossi G,Cavazza A,Marchioni A,et al. Role of chemotherapy and the receptor tyrosine kinases kit,pdgfralpha,pdgfrbeta,and met in large-cell neuroendocrine carcinoma of the lung[J]. J Clin Oncol,2005,23(34):8774-8785. DOI:10.1200/JCO.2005.02.8233. [2] Iyoda A,Makino T,Koezuka S,et al. Treatment options for patients with large cell neuroendocrine carcinoma of the lung[J]. Gen Thorac Cardiovasc Surg,2014,62(6):351-356. DOI:10.1007/s11748-014-0379-9. [3] Sun YH,Lin SW,Hsieh CC,et al. Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung[J]. Ann Thorac Surg,2014,98(3):1013-1019. DOI:10.1016/j.athoracsur.2014.05.012. [4] Sakurai H,Asamura H. Large-cell neuroendocrine carcinoma of the lung:Surgical management[J]. Thorac Surg Clin,2014,24(3):305-311. DOI:10.1016/j.thorsurg.2014.05.001. [5] 方三高,许春伟,肖华亮,等. 解读2015年WHO肺、胸膜、胸腺及心脏肿瘤分类(肺)[J]. 重庆医学,2017(1):4-23. DOI:10.3969/j.issn.1671-8348.2017.01.002. Fang SG,Xu CH,Xiao HL,et al. Interpretation of WHO classification of lung, pleura, thymus and cardiac tumors (lung) in 2015[J]. Chongqing Med,2017(1):4-23. DOI:10.3969/j.issn.1671-8348.2017.01.002. [6] Asamura H,Kameya T,Matsuno Y,et al. Neuroendocrine neoplasms of the lung:A prognostic spectrum[J]. J Clin Oncol,2006,24(1):70-76. DOI:10.1200/JCO.2005.04.1202. [7] Iyoda A,Hiroshima K,Moriya Y,et al. Prospective study of adjuvant chemotherapy for pulmonary large cell neuroendocrine carcinoma[J]. Ann Thorac Surg,2006,82(5):1802-1807. DOI:10.1016/j.athoracsur.2006.05.109. [8] Iyoda A,Hiroshima K,Moriya Y,et al. Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma[J]. J Thorac Cardiovasc Surg,2009,138(2):446-453. DOI:10.1016/j.jtcvs.2008.12.037. [9] Fournel L,Falcoz PE,Alifano M,et al. Surgical management of pulmonary large cell neuroendocrine carcinomas:A 10-year experience[J]. Eur J Cardiothorac Surg,2013,43(1):111-114. DOI:10.1093/ejcts/ezs174. [10] Saji H,Tsuboi M,Matsubayashi J,et al. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy[J]. Anticancer Drugs,2010,21(1):89-93. DOI:10.1097/CAD.0b013e328330fd79. [11] Filosso PL,Guerrera F,Evangelista A,et al. Adjuvant chemotherapy for large-cell neuroendocrine lung carcinoma:Results from the european society for thoracic surgeons lung neuroendocrine tumours retrospective database[J]. Eur J Cardiothorac Surg,2017,52(2):339-345. DOI:10.1093/ejcts/ezx101. [12] Kujtan L,Muthukumar V,Kennedy KF,et al. The role of systemic therapy in the management of stage i large cell neuroendocrine carcinoma of the lung[J]. J Thorac Oncol,2018,13(5):707-714. DOI:10.1016/j.jtho.2018.01.019. [13] Kenmotsu H,Niho S,Ito T,et al. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer)[J]. Lung Cancer,2014,84(3):254-258. DOI:10.1016/j.lungcan.2014.03.007. [14] Tang H,Wang H,Xi S,et al. Perioperative chemotherapy with pemetrexed and cisplatin for pulmonary large-cell neuroendocrine carcinoma:a case report and literature review[J]. Oncol Targets Ther,2018,11(7):2557-2563. DOI:10.2147/OTT. S160565. [15] Tsoukalas N,Baxevanos P,Aravantinou-Fatorou E,et al. Advances on systemic treatment for lung neuroendocrine neoplasms[J]. Ann Transl Med,2018,6(8):146. DOI:10.21037/atm.2018.04.03. [16] Sun JM,Ahn MJ,Ahn JS,et al. Chemotherapy for pulmonary large cell neuroendocrine carcinoma:Similar to that for small cell lung cancer or non-small cell lung cancer?[J]. Lung Cancer,2012,77(2):365-370. DOI:10.1016/j.lungcan.2012.04.009. [17] Sánchez de Cos Escuín, J. Diagnosis and treatment of neuroendocrine lung tumors[J]. Arch Bronconeumol,2014,50(9):392-396. DOI:10.1016/j.arbres.2014.02.004. [18] Varlotto JM,Medford-Davis LN,Recht A,et al. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas?[J]. J Thorac Oncol,2011,6(6):1050-1058. DOI:10.1097/JTO.0b013e318217b6f8. [19] Naidoo J,Santos-Zabala ML,Iyriboz T,et al. Large cell neuroendocrine carcinoma of the lung:Clinico-pathologic features,treatment,and outcomes[J]. Clin Lung Cancer,2016,17(5):e121-e129. DOI:10.1016/j.cllc.2016.01.003. [20] Le Treut J,Sault MC,Lena H,et al. Multicentre phase ii study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma:The gfpc 0302 study[J]. Ann Oncol,2013,24(6):1548-1552. DOI:10.1093/annonc/mdt009. [21] Niho S,Kenmotsu H,Sekine I,et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung:A multicenter phase ii study[J]. J Thorac Oncol,2013,8(7):980-984. DOI:10.1097/JTO.0b013e31828f6989. [22] Christopoulos P,Engel-Riedel W,Grohe C,et al. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma:a multicenter phase ii trial[J]. Ann Oncol,2017,28(8):1898-1902. DOI:10.1093/annonc/mdx268. [23] Mazieres J,Daste G,Molinier L,et al. Large cell neuroendocrine carcinoma of the lung:Pathological study and clinical outcome of 18 resected cases[J]. Lung Cancer,2002,37(3):287-292. DOI:10.1016/S0169-5002(02)00099-5. [24] Ricciuti B,Metro G,Ferolla P,et al. Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received:A single institution analysis[J]. Ann Oncol,2015,26(1):78-78. DOI:10.1093/annonc/mdv343.16. [25] Metro G,Ricciuti B,Chiari R,et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung:Implications for clinical practice[J]. Lung Cancer,2016,95(1):82-87. DOI:10.1016/j.lungcan.2016.03.006. [26] Rieber J,Schmitt J,Warth A,et al. Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas[J]. Eur J Med Res,2015,20(1):64. DOI:10.1186/s40001-015-0158-9. [27] Fasano M,Della Corte CM,Papaccio F,et al. Pulmonary large-cell neuroendocrine carcinoma:From epidemiology to therapy[J]. J Thorac Oncol,2015,10(8):1133-1141. DOI:10.1097/JTO.0000000000000589. [28] Prelaj A,Rebuzzi SE,Del Bene G,et al. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in lcnec[J]. ERJ Open Res,2017,3(1):00128-2016. DOI:10.1183/23120541.00128-2016. [29] Filosso PL,Ruffini E,Oliaro A,et al. Large-cell neuroendocrine carcinoma of the lung:a clinicopathologic study of eighteen cases and the efficacy of adjuvant treatment with octreotide[J]. J Thorac Cardiovasc Surg,2005,129(4):819-824. DOI:10.1016/j.jtcvs.2004.05.023. [30] Yoshida H,Sekine I,Tsuta K,et al. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung[J]. Jpn J Clin Oncol,2011,41(7):897-901. DOI:10.1093/jjco/hyr065. [31] Kasahara N,Wakuda K,Omori S,et al. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma[J]. Mol Clin Oncol,2017,6(5):718-722. DOI:10.3892/mco.2017.1198. [32] Kenmotsu Y,Oshita F,Sugiura M,et al. Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung[J]. Anticancer Res,2012,32(4):1453-1456. [33] Kozuki T,Fujimoto N,Ueoka H,et al. Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma[J]. J Cancer Res Clin Oncol,2005,131(3):147-151. DOI:10.1007/s00432-004-0626-z. [34] Yoshida Y,Ota S,Murakawa T,et al. Combined large cell neuroendocrine carcinoma and adenocarcinoma with epidermal growth factor receptor mutation in a female patient who never smoked[J]. Ann Thorac Cardiovasc Surg,2014,20 Suppl:582-584. DOI:10.5761/atcs.cr.12.02217. [35] De Pas TM,Giovannini M,Manzotti M,et al. Large-cell neuroendocrine carcinoma of the lung harboring egfr mutation and responding to gefitinib[J]. J Clin Oncol,2011,29(34):e819-822. DOI:10.1200/JCO.2011.36.2251. [36] Yanagisawa S,Morikawa N,Kimura Y,et al. Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation:Possible transformation of lung adenocarcinoma[J]. Respirology,2012,17(8):1275-1277. DOI:10.1111/j.1440-1843.2012.02258.x. [37] Wang Y,Shen YH,Ma S,et al. A marked response to icotinib in a patient with large cell neuroendocrine carcinoma harboring an egfr mutation:a case report[J]. Oncol Lett,2015,10(3):1575-1578. DOI:10.3892/ol.2015.3405. [38] Iyoda A,Travis WD,Sarkaria IS,et al. Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma[J]. Exp Ther Med,2011,2(6):1041-1045. DOI:10.3892/etm.2011.343. [39] Yokouchi H,Kitahashi M,Oshitari T,et al. Intravitreal bevacizumab for iris tumor metastasized from large cell neuroendocrine carcinoma of lung[J]. Graefes Arch Clin Exp Ophthalmol,2013,251(9):2243-2245. DOI:10.1007/s00417-012-2218-y. [40] Tsuruoka K,Horinouchi H,Goto Y,et al. Pd-l1 expression in neuroendocrine tumors of the lung[J]. Lung Cancer,2017,108(1):115-120. DOI:10.1016/j.lungcan.2017.03.006. [41] Wang VE,Urisman A,Albacker L,et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden[J]. J Immunother Cancer,2017,5(1):75. DOI:10.1186/s40425-017-0281-y. [42] Weber MM,Fottner C. Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia[J]. Oncol Res Treat,2018,41(5):306-312. DOI:10.1159/000488996. [43] Hiroshima K,Mino-Kenudson M. Update on large cell neuroendocrine carcinoma[J]. Transl Lung Cancer Res,2017,6(5):530-539. DOI:10.21037/tlcr.2017.06.12. [44] George J,Walter V,Peifer M,et al. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors[J]. Nat Commun,2018,9(1):1048. DOI:10.1038/s41467-018-03099-x. [45] Derks JL,Leblay N,Thunnissen E,et al. Molecular subtypes of pulmonary large-cell neuroendocrine carcinoma predict chemotherapy treatment outcome[J]. Clin Cancer Res,2018,24(1):33-42. DOI:10.1158/1078-0432. CCR-17-1921. [46] Hanna N,Johnson D,Temin S,et al. Systemic therapy for stage iv non-small-cell lung cancer:American society of clinical oncology clinical practice guideline update[J]. J Clin Oncol,2017,JCO2017746065. DOI:10.1200/JCO.2017.74.6065. [47] Lo Russo G,Pusceddu S,Proto C,et al. Treatment of lung large cell neuroendocrine carcinoma[J]. Tumour Biol,2016,37(6):7047-7057. DOI:10.1007/s13277-016-5003-4.
2019, Vol. 28 
